Our MIT CCSB Tumor Cell Networks Center is directed toward achieving three overarching objectives: Objective 1 - Cancer Research: advance the development and application of new systems biology approaches to cancer research in three significant scientific areas (mitogenesis, migration, and DNA damage/repair) and improve corresponding approaches for discovery and use of cancer therapies;Objective 2 - Education: train a new generation of young research leaders comfortable at the interdisciplinary interface between experimental molecular/cell biology and quantitative modeling in key areas of basic and applied cancer research;Objective 3 - Collaboration and Outreach: serve the general cancer biology community by acting as a collaborative partner that brings new ideas and methods to a wide community of investigators regardless of institutional affiliation. A central thread integrating our experiment and modeling efforts is a paradigmatic 'cue-signal-response'framework for probing and modeling the regulation of tumor cell phenotypes critical to tumor cell biology.
We aim to develop and make available to the cancer biology community successful models of three distinct but inter-related classes of models: 'Cell Response'models, capable of predicting how cellular phenotypes are executed by biophysical molecular processes;'Signal-Response'models, capable of predicting how cellular responses are regulated by information carried by intracellular signaling pathways;and 'Cue-Signal'models, capable of predicting what intracellular signals are generated by environmental stimuli and therapeutic agents in the context of specific genotypes. The construction and testing of all three classes of models is currently underway and linked to three important problems in cancer biology and therapy: (a) cancer progression via dysregulation of mitogenic signaling pathways downstream of receptor tyrosine kinases;(b) cancer progression via inappropriate cell migration processes that promote invasive and metastatic behavior;and (c) cancer treatment via molecular pharmaceuticals including chemotherapeutics and targeted inhibitors. Our Education and Outreach activities include participation in regular meetings of a student/postdoc/faculty systems biology community at MIT as well as dedicated seminars and retreats, offering of curricular subjects, short courses, conference sessions, and symposia related to cancer systems biology. We also are proactive in making our data, models, and publications available on our website, and in collaborative interactions with cancer biology investigators at other institutions.

Public Health Relevance

The purpose of the NCI CCSB initiative as stated in RFA-CA-09-011 is: to stimulate the development and apphcation of the integrative systems approaches and mathematical/computational modeling to cancer research... specifically in the areas of (a) cancer biology;(b) experimental therapeutics;(c) early interventions;and (d) cancer susceptibihty. Our MIT CCSB Tumor Cell Networks Center focus will fall centrally within Area (a), cancer biology, with intersection into Area (b), experimental therapeutics.

National Institute of Health (NIH)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Gallahan, Daniel L
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Massachusetts Institute of Technology
Internal Medicine/Medicine
Schools of Arts and Sciences
United States
Zip Code
Zhao, Boyang; Hemann, Michael T; Lauffenburger, Douglas A (2014) Intratumor heterogeneity alters most effective drugs in designed combinations. Proc Natl Acad Sci U S A 111:10773-8
Bell, Eric L; Nagamori, Ippei; Williams, Eric O et al. (2014) SirT1 is required in the male germ cell for differentiation and fecundity in mice. Development 141:3495-504
Arneja, Abhinav; Johnson, Hannah; Gabrovsek, Laura et al. (2014) Qualitatively different T cell phenotypic responses to IL-2 versus IL-15 are unified by identical dependences on receptor signal strength and duration. J Immunol 192:123-35
Krueger, Andrew T; Kroll, Carsten; Sanchez, Edgar et al. (2014) Tailoring chimeric ligands for studying and biasing ErbB receptor family interactions. Angew Chem Int Ed Engl 53:2662-6
Beck, Jon R; Peterson, Laura B; Imperiali, Barbara et al. (2014) Quantification of protein kinase enzymatic activity in unfractionated cell lysates using CSox-based sensors. Curr Protoc Chem Biol 6:135-56
Niepel, Mario; Hafner, Marc; Pace, Emily A et al. (2014) Analysis of growth factor signaling in genetically diverse breast cancer lines. BMC Biol 12:20
Johnson, Hannah; White, Forest M (2014) Quantitative analysis of signaling networks across differentially embedded tumors highlights interpatient heterogeneity in human glioblastoma. J Proteome Res 13:4581-93
Hemann, Michael T (2014) From breaking bad to worse: exploiting homologous DNA repair deficiency in cancer. Cancer Discov 4:516-8
Buck, Lorenna D; Inman, S Walker; Rusyn, Ivan et al. (2014) Co-regulation of primary mouse hepatocyte viability and function by oxygen and matrix. Biotechnol Bioeng 111:1018-27
Morton, Stephen W; Lee, Michael J; Deng, Zhou J et al. (2014) A nanoparticle-based combination chemotherapy delivery system for enhanced tumor killing by dynamic rewiring of signaling pathways. Sci Signal 7:ra44

Showing the most recent 10 out of 122 publications